Atlas FDA

Oncomine Dx Target Test

FDA premarket approval P160045/S013 · decided 2019-02-13

Approval details

PMA number
P160045
Supplement
S013
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Oncomine Dx Target Test
Generic name
Next generation sequencing oncology panel, somatic or germline variant detection system
Applicant
Life Technologies Corporation
Date received
2019-01-25
Decision date
2019-02-13
Days to decision
19 days
Decision code
OK30
Product code
PQP
Advisory committee
Pathology
Expedited review
No
Location
Carlsbad, CA
Statement
Addition of in-process concentration measurements of device sub-components.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel (K241806)Life Technologies Corporation2025-01-08
Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit (K233453)Life Technologies Corporation2024-07-10
Applied Biosystems™ 3500 Dx Genetic Analyzer and Applied Biosystems™ 3500xL Dx Genetic Analyzer (K191030)Life Technologies Corporation2020-02-21
Ion PGM Dx System (K170299)Life Technologies Corporation2017-06-22
QUANTSTUDIO DX REAL-TIME PCR INSTRUMENT (K123955)Life Technologies Corporation2013-03-08
STEMPRO MSC SFM (K103302)Life Technologies Corporation2011-02-18
KNOCKOUT SR MEDIUM, KNOCKOUT SR XENOFREE MEDIUM MODEL 10828, 12618 (K100616)Life Technologies Corporation2010-05-20